Kristin Khalaf, PhD

Employed by large health care organization withing the GHEOR service line. Conduct various type of research for different pharmaceutical industry clients. This includes medical communication, economic models, data analysis, HEOR strategy, and outcomes research (PRO-related activities, surveys research).
Status: 
Alumni
Degree: 
PhD
Program: 
Pharmaceutical Sciences
Track: 
Pharmaceutical Economics, Policy and Outcome
Dissertation Title: 
Evaluation of the Measurement Properties of the Short Form 36 version 2 Health Survey in a Sample of Patients with Multiple Sclerosis
Year Enrolled: 
2012
Phone: 
520-626-7265
Education: 
M.S., Pharmaceutical Sciences (2011) University of Arizona, Tucson, AZ PharmD (2009) University of Southern California School of Pharmacy, Los Angeles, CA B.S. Molecular & Cell Biology (2004) University of California, Berkeley, Berkeley, CA
Research Interests: 
I collaborate with Allergan Pharmaceuticals to do various projects with them. My major project for this year is to compare the health-related quality of life of patients with selected neurogenic diseases in the presence or absence of urinary incontinence.
Honors and Achievements: 
1. Graduate Track Awards: Academic Excellence, 2013-14.
Publications: 
1. Khalaf KM, Coyne K, Globe D, Armstrong E, Malone D, Burks J. The Impact of Lower Urinary Tract Symptoms on Health-Related Quality of Life Among Patients with Multiple Sclerosis. Preprint version available online, Neurourology and Urodynamics.
2. Khalaf KM, Coyne K, Globe D, Armstrong E, Malone D, Burks J. Urinary Symptom Treatment Patterns Among Patients with Multiple Sclerosis. Preprint version available online, International Journal of Multiple Sclerosis Care.
3. Cuervo J, Castejon N, Khalaf KM, Globe D, Corbell C, Patrick DL. Development of the Incontinence Utility Index: estimating population-based utilities associated with urinary problems from the Incontinence Quality of Life Questionnaire and its Neurogenic Module. Health and Quality of Life Outcomes, 2014, 12:147.
4. Tang D, Colayco D, Khalaf K, Piercy J, Patel V, Globe D, Ginsberg D. Impact of Urinary Incontinence on Healthcare Resource Utilization, Health-related Quality of Life and Productivity in Patients with Overactive Bladder. British Journal Of Urology International, 2014;113(3): 484-491.
5. Ruffion A, Castro-Diaz D, Patel H, Khalaf KM, Onyenwenyi A, Globe D, LeReun C, Teneishvili M, Edwards M. Systematic Review and Meta-Analysis of the Epidemiology of Incontinence in Neurological Conditions. Neuroepidemiology, 2013;41(3-4):146-55.
6. Patrick DL, Khalaf KM, Dmochowski R, Saha S, Kowalski J, Globe D. Psychometric Validation of the Incontinence Quality of Life Questionnaire in Patients with Idiopathic Overactive Bladder. Clinical Therapeutics, 2013; June 35(6): 836-45.
7. Kay S, Anderson P, Colayco D, Khalaf KM, Globe D, Tolley K. Mapping EQ-5D Utility Scores From the Incontinence Quality of Life Questionnaire among Patients with Neurogenic and Idiopathic Overactive Bladder. Value in Health, 2013; 16(2): 394-402.
8. Tapia C, Khalaf KM, Berenson K, Globe D, Chancellor M, Carr L. Health-related Quality of Life and Economic Impact of Urinary Incontinence due to Neurogenic Detrusor Overactivity Associated with a Neurologic Condition. Health and Quality of Life Outcomes, 2013; 11:13.
9. Freemantle N, Khalaf K, Loveman C, Stanisic S, Gultyaev D, Lister J, Drake M. OnabotulinumtoxinA in the Treatment of Overactive Bladder: a Cost-Effectiveness Analysis versus Best Supportive Care in England and Wales. Eur J Health Econ. 2015 Oct 19. [Epub ahead of print]
10. Castejon N, Khalaf K, Ni Q, Cuervo J, Patrick DL. Psychometric Properties of the Incontinence Utility Index Among Patients with Idiopathic Overactive Blasser: Data from Two Multicenter, Double-blind, Randomized, Phase 3, Placebo-controlled Clinical Trials. Health Qual Life Outcomes. 2015 Aug 1;13.116.
11. Freemantle N, Ginsberg DA, McCool R, Fleetwood K, Arber M, Khalaf K, Loveman C, Ni Quanhong, Glanville J. A Comparative Assessment of OnabotulinumtoxinA (BOTOX®) and Mirabegron for Overactive Bladder: An Indirect Treatment Comparison. BMJ Open. 2016 Feb 23; 6(2):e009122.
12. Everaert K, Gruenenfelder J, Schulte-Baukloh H, Egerdie B, Khalaf K, Ni Q, Sussman D. Impact of onabotulintoxinA on quality of life and practical aspects of daily living: A pooled analysis of two randomized controlled trials. Int J Urol. 2015 Dec;22(12):1131-7.
13. Chartier-Kastler E, Rovner E, Hepp Z, Khalaf K, Ni Q, Chancellor M, Patient Reported Goal Achievement Following OnabotulinumtoxinA Treatment in Patients with Neutogenic Detrusor Overactivity. Neurourol Urodyn. 2016 Jun; 35(5): 595-600.
Alumna or Alumnus: 
Alumna
Alumni Title/Position/Employer: 
Assistant Director, Global Health Economics and Outcomes Research (GHEOR), Xcenda
Career Type: 
Industry
Contact Info Release: 
For Publication